a New Front
in the War against Cancer
developing advanced therapies designed
to target and destroy the deadliest cancers
- melanoma, liver and breast - while
minimizing side effects
An Investigational Drug for Cancer
An Investigational Drug for Psoriasis and Atopic Dermatitis
Provectus will hold its quarterly business update conference call at 5 p.m. (EST) November 5, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.
A BioPharm Insight article reports that Provectus' is planning two Phase III trials of PH-10 to begin in mid-2016.
P&T meeting highlights for ESMO 17th World Congress on Gastrointestinal Cancer includes coverage of the Phase 1 study of PV-10 for chemoablation of hepatocellular cancer and cancer metastatic to the liver.
An article appearing in the Journal of Cutaneous Medicine and Surgery discusses recent advances in the treatment of advanced melanoma.
A Healio Dermatology article covers news that Provectus has initiated a Phase 1b/2 clinical trial of PV-10 in combination with Keytruda® for the treatment of stage IV melanoma.
A report on PV-10 liver study data appears at the top of an Oncology News article entitled "Reports from ESMO 17th World Congress on Gastrointestinal Cancer."
Investing News Network recently published an article in the Life Science section covering news of the grant by the US PTO of a patent, shared jointly by Provectus and Pfizer, covering PV-10 when used in combination with select melanoma and liver cancer therapies.
Provectus will hold its quarterly business update conference call at 4 p.m. (EDT) August, 2015 to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.
At the World Cutaneous Malignancies Congress meeting at Personalized Medicine in Oncology's PMO Live 2015 conference, a presentation entitled "Overview of Intralesional Therapy in Melanoma" was presented by Dr. Sanjiv Agarwala.
In an article appearing in The ASCO Post, Robert Andtbacka, MD discusses the use of intralesional anti-cancer agents that induce a systemic immune response.
A Pharmiweb article discusses data from the phase 1 trial of PV-10 for liver cancer that includes two patients that demonstrated non-existent liver cancer after a single injection of PV-10.
An article appearing in Medical News Today discusses studies of investigational drugs for treating HCC and metastatic liver cancer that were presented at ESMO GI 2015.
An article appearing on FiercePharmaAsia reports that Boehringer Ingelheim will work with Provectus to register cancer candidate PV-10 in China in return for priority rights in the country on commercialization.
An article appearing on DocGuide reports on promising clinical studies of locoregional liver cancer treatments that were presented at the 2015 ESMO World Congress on Gastrointestinal Cancer.
An eCancer News article reports on data from the phase 1 study of PV-10 for liver cancer that was recently presented at ESMO 2015.
An article appearing in the Knoxville News Sentinel covers news of Provectus partnering with global pharmaceutical company Boehringer Ingelheim to help bring to market its investigative drug for cancer, PV-10, in mainland China, Hong Kong and Taiwan.
ChinaBio Today reports on Provectus - Boehringer Ingelheim letter of intent to collaborate on bringing PV-10 for melanoma and cancers of the liver to market in China.
Provectus presented at the BIO International Convention 2015 in Philadelphia on June 16, 2015 at 10:45 AM EDT.
A Melanoma News Today article reports on the comencement of enrollment for a phase 3 trial of PV-10 for locally advanced cutaneous melanoma.
A Melanoma News Today article reports on a presentation entitled "A Changing Topography: The Role of Intralesional Therapy in Melanoma" that was presented by Dr. Sanjiv Agarwala at ASCO 2015. In the presentation, Dr. Agarwala showed phase 2 findings for PV-10, showing the drug accumulated within cancer cells but not normal cells, inducing acute autophagy and exposing antigenic tumor fragments to antigenic presenting cells (APCs).
Provectus today announced that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1," at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland.
Provectus today announced its results of operations and financial condition for the third quarter ended September 30, 2015.
Provectus announced today that it will hold its 2015 third quarter business update conference call at 5 pm Eastern Standard Time on Thursday, November 5, 2015.
Provectus today reported that the Journal of Clinical and Cellular Immunology has published a paper titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses."
Provectus today announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma.
Provectus today announced that it has completed patient accrual for its phase 2 study of the cellular and immunologic changes in the skin of patients receiving PH-10, an investigational topical treatment for atopic dermatitis and psoriasis.
Provectus today announced that it has received a patent from the US Patent and Trademark Office, U.S. Patent number 9,107,887. The patent protects the use of PV-10 in combination with certain other types of drugs in the treatment of melanoma and cancers of the liver.
Provectus today announced its results of operations and financial condition for the second quarter ended June 30, 2015.
Provectus announced today that it will hold its 2015 second quarter business update conference call at 4 pm Eastern Daylight Time on Thursday, August 6, 2015.
Provectus announced that it continues to work with Sinopharm-China State Institute of Pharmaceutical Industry and Sinopharm A-Think Pharmaceutical Co., Ltd to reach an agreement on PV-10 use in China.
Provectus announced today that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented on July 3, 2015 at the 6th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2015) in Osaka, Japan.
Provectus announced today that it has signed a Letter of Intent (the "LOI") with Boehringer Ingelheim (China) Investment Co. Ltd. ("Boehringer").
Provectus announced that data from its phase 1 study of PV-10 for chemoablation of hepatocellular carcinoma (HCC) and cancer metastatic to the liver was presented at the ESMO 17th World Congress on Gastrointestinal Cancer (ESMO-GI).
The American Association of Physicians of Indian Origin ("AAPI") honored Provectus Biopharmaceuticals, Inc. at a gala during the AAPI's 33rd Annual Convention and Scientific Assembly on Friday, June 19, 2015.
Provectus today announced that Dr. Vernon Sondak (Moffitt Cancer Center, Tampa, FL, USA) presented data on "Intralesional Therapy for Melanoma with PV-10" during the 5th European Post-Chicago Melanoma/Skin Cancer Meeting in Munich, Germany.
Provectus announced that its poster presentation titled "Trials in Progress: Intralesional Rose Bengal vs Systemic Chemotherapy for Treatment of Locally Advanced Cutaneous Melanoma" is on display at the 5th European Post-Chicago Melanoma / Skin Cancer Meeting in Munich, Germany.
Provectus announced that the abstract titled, "Phase 1 Study of PV-10 for Chemoablation of Hepatocellular Cancer and Cancer Metastatic to the Liver" to be presented at the ESMO 17th World Congress on Gastrointestinal Cancer is now available online at: http://annonc.oxfordjournals.org/content/26/suppl_4/iv33.1.full?sid=82267ebd-da5c-4a1a-9320-a795571b6085
Provectus announced today that it has completed its public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock at a price to the public of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.
Provectus announced that it has retained healthcare communications company PharmaHEALTHLabs to coordinate and facilitate an Investigator Advisory Board meeting to be held during 11th Brazilian Melanoma Conference from August 13-15, 2015 in Goiania, Brazil.
Provectus today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock with a public offering price of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock.
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.